Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media

Sunderland, R; McVey, Donna; Atkin, Karen J.

doi:10.1016/s0011-393x(05)80723-4

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the overall incidence of protocol‐defined diarrhoea, determined from data recorded in diary booklets, was very low (bid 2.7%; tid 4.3%) and the difference in incidence between the two treatment groups was not statistically significant. These diarrhoea rates, which are lower than those previously reported for amoxycillin/clavulanate, 11–12 may be accounted for by the data‐collection methods used in this study, which were less subjective and more consistent than the reporting of diarrhoea as an adverse experience.…”

Section: Discussioncontrasting

confidence: 54%

Efficacy of Twice‐daily Amoxycillin/Clavulanate (‘Augmentin‐duo’ 400/57) in Mild to Moderate Lower Respiratory Tract Infection in Children

Cook¹,

Zachariah

Cree

et al. 1996

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY A new amoxycillin/clavulanate regimen (‘Augmentin‐Duo’ 400/57), to be given orally in two divided doses, has been proposed to overcome the inconvenience of tid dosing. This observer‐blind, multicentre study randomised children aged two to 12 years with lower respiratory tract infection to seven days' treatment with either amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day (221 patients) or the currently prescribed amoxycillin/clavulanate regimen of 20/5mg/kg/day tid (216 patients). Clinical success (cure) rates at follow up were 81.0% for the bid group and 77.8% for the tid group [difference 3.2%; 95% CI (‐4.36, 10.80)], indicating that the regimens were of equivalent efficacy. Both regimens were well tolerated, and there was no statistically significant difference in the incidence of adverse experiences between the two groups. Compliance with study medication was high and similar for both groups (80% compliance: bid 90.0%; tid 87.0%).

show abstract

Section: Discussioncontrasting

confidence: 54%

Efficacy of Twice‐daily Amoxycillin/Clavulanate (‘Augmentin‐duo’ 400/57) in Mild to Moderate Lower Respiratory Tract Infection in Children

Cook¹,

Zachariah

Cree

et al. 1996

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children

Behre

Burow²,

Quinn

et al. 1997

Infection

View full text Add to dashboard Cite

Children with acute otitis media (AOM), aged 2-12 years, were randomised to 10 days treatment with amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d. (231 patients) or to A/C 60/15 mg/kg/day given t.i.d. (232 patients). Clinical success rates at end of therapy (10-17 days) were 91.8% for the b.i.d. group and 90.5% for the t.i.d. group and at follow-up (28-42 days) were 80.1% for the b.i.d. group and 77.6% for the t.i.d. group, indicating that the b.i.d. regimen was as effective as the t.i.d. regimen. There was no statistically significant difference in incidence of adverse experiences between the two groups. The overall incidence of protocol defined diarrhoea assessed from diary booklets was low, with a lower incidence in the b.i.d. group (6.7%) than in the t.i.d. group (10.3%). Significantly more patients in the b.i.d. group (83.1%) than in the t.i.d. group (72.8%) had at least 80% compliance over a 7-10 day treatment period. A/C given twice or three-times daily was highly effective in the treatment of AOM in children. The two regimens showed equivalent clinical efficacy, both were well tolerated, and there was evidence of improved compliance with the b.i.d. regimen.

show abstract

Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: A systematic literature review

Riet‐Nales

Schobben

Egberts

et al. 2010

Clinical Therapeutics

View full text Add to dashboard Cite

Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media

Cited by 6 publications

References 9 publications

Efficacy of Twice‐daily Amoxycillin/Clavulanate (‘Augmentin‐duo’ 400/57) in Mild to Moderate Lower Respiratory Tract Infection in Children

Efficacy of Twice‐daily Amoxycillin/Clavulanate (‘Augmentin‐duo’ 400/57) in Mild to Moderate Lower Respiratory Tract Infection in Children

Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children

Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: A systematic literature review

Contact Info

Product

Resources

About